Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Background/aims Non-functioning pancreatic endocrine tumours (NFPET) constitute the largest component (35-50%) of pancreatic endocrine tumours. They are characterized by the absence of symptoms of hormone hypersecretion and frequently have clinical manifestations similar to the more common exocrine pancreatic adenocarcinoma. The present studyaims toevaluate the clinical features, diagnostic approach and, in particular, the significance of serum chromogranin A levels (CgA) in the management and outcome of 42 patients with NFPET (from a series of 121 patients with pancreatic endocrine tumours). Methods Twenty-five males and 17 females were included, and the mean age at diagnosis was 52.3 years (range: 26-68 years). The diagnosis for each patient was established by histopathological examination and immunohistochemistry. After the histopathological confirmation of diagnosis and during the follow-up period, patients were evaluated clinically and radiologically (including OctreoScan), whilst fasting gut hormones (including CgA) were also estimated. At diagnosis, all patients were checked for the presence of multiple endocrine neoplasia type I syndrome. The follow-up was complete and ranged from 12 to 86 months (mean: 49 months). Results Dyspepsia (66.5%) and weight loss (47.6%) were the most common symptoms at diagnosis, while in 21.4% of patients tumour lesions were revealed incidentally. Plasma CgA levels were significantly or moderately elevated in all patients with liver metast…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All patients with metastatic disease had elevated CgA concentrations whereas half of patients with localized disease had elevated CgA, strengthening the idea that CgA is more sensitive in disseminated disease compared to localized disease [16,17,18,30,31].”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [31]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Endocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas
(2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4059-0.x5001-2 · Cited by 449
Panzuto, F., Nasoni, S., Falconi, M., Corleto, V. D., Capurso, G., Cassetta, S., Di Fonzo, M., Tornatore, V., Milione, M., Angeletti, S., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01017 · Cited by 391
Dromain, C., de Baere, T., Lumbroso, J., Caillet, H., Laplanche, A., Boige, V., Ducreux, M., Duvillard, P., Elias, D., Schlumberger, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.013 · Cited by 389
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Bodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 305
Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases
Berber, E., Flesher, N., & Siperstein, A. E. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6629-5 · Cited by 236
Research works printed but not linked: 2
- Nikou, 1995, Somatostatin-receptor imaging in the diagnosis and management of gut endocrine tumours, Hell J Gastroenterol, 8, 312
- Ducreux, 2000, The antitumoural effect of the long-acting somatostatin analogue lanreotide in neuroendocrine tumours, Am J Gastroenterol, 95, 3276, 10.1111/j.1572-0241.2000.03210.x · doi:10.1111/j.1572-0241.2000.03210.x · Paper page
Cited by
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Halfdanarson, T. R., Strosberg, J. R., Tang, L., Bellizzi, A. M., Bergsland, E. K., O'Dorisio, T. M., Halperin, D. M., Fishbein, L., Eads, J., Hope, T. A., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001597 · Cited by 202
Lawrence, B., Gustafsson, B. I., Kidd, M., Pavel, M., Svejda, B., & Modlin, I. M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.001 · Cited by 169
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
Ter‐Minassian, M., Chan, J. A., Hooshmand, S. M., Brais, L. K., Daskalova, A., Heafield, R., Buchanan, L., Qian, Z. R., Fuchs, C. S., Lin, X., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0340 · Cited by 132
Pfeifer, A. K., Gregersen, T., Grønbæk, H., Hansen, C. P., Müller‐Brand, J., Bruun, K. H., Krogh, K., Kjær, A., & Knigge, U. (2011) · Neuroendocrinology · doi:10.1159/000324096 · Cited by 130
Kulke, M. H., Ruszniewski, P. B., Cutsem, E. V., Lombard‐Bohas, C., Valle, J. W., de Herder, W. W., Pavel, M. E., Degtyarev, E., Brase, J. C., Bubuteishvili‐Pacaud, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx078 · Cited by 107
A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
Mohammed, T. A., Holen, K. D., Jaskula-Sztul, R., Mulkerin, D., Lubner, S. J., Schelman, W. R., Eickhoff, J., Chen, H., & LoConte, N. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0031 · Cited by 89
Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
Giacinto, P. D., Rota, F., Rizzà, L., Campana, D., Isidori, A. M., Lania, A. G., Lenzi, A., Zuppi, P., & Baldelli, R. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8126087 · Cited by 74
Pancreastatin Predicts Survival in Neuroendocrine Tumors
Sherman, S. K., Maxwell, J. E., O'Dorisio, M. S., O’Dorisio, T. M., & Howe, J. R. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3728-0 · Cited by 70
Prognostic and predictive biomarkers in neuroendocrine tumours
Chan, D. L. H., Clarke, S. J., Diakos, C. I., ROACH, P. J., Bailey, D. L., Singh, S., & Pavlakis, N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.017 · Cited by 59
Rossi, R. E., Ciafardini, C., Sciola, V., Conte, D., & Massironi, S. (2018) · Pancreas · doi:10.1097/mpa.0000000000001184 · Cited by 61
Han, X., Zhang, C., Tang, M., Xu, X., Liu, L., Ji, Y., Pan, B., & Lou, W. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000332 · Cited by 55
Singh, S., & Law, C. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.15 · Cited by 59
Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors
Conlon, J. M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.11.013 · Cited by 50
Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers
Herrera-Martínez, A. D., Hofland, L. J., Moreno, M. Á. G., Castano, J. P., de Herder, W. W., & Feelders, R. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0354 · Cited by 49
Chou, W., Hung, Y., Hsu, J., Chen, J., Lu, C., Hwang, T., Rau, K., Yeh, K., Chen, T., & Sun, C. (2012) · Neuroendocrinology · doi:10.1159/000333853 · Cited by 46
Kim, J. Y., Kim, K., Kim, K., Park, I. J., Lee, J. L., Myung, S., Park, Y., Park, Y.-S., Yu, C. S., Kim, J. C., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000400 · Cited by 46
Prognostic Significance of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors
Kim, M. K., Warner, R. R. P., Ward, S. C., Harpaz, N., Roayaie, S., Schwartz, M., Itzkowitz, S. H., & Wisnivesky, J. P. (2015) · Neuroendocrinology · doi:10.1159/000371807 · Cited by 44
Surgical management of pancreatic neuroendocrine tumors
Kimura, W., Tezuka, K., & Hirai, I. (2011) · Surgery Today · doi:10.1007/s00595-011-4547-6 · Cited by 44
Helle, K. B. (2010) · Results and problems in cell differentiation · doi:10.1007/400_2009_26 · Cited by 44
Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., et al. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8327 · Cited by 43
Modlin, I. M., Moss, S. F., Gustafsson, B. I., Lawrence, B. J., Schimmack, S. J., & Kidd, M. S. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0794-7 · Cited by 43
Preoperative Assessment of the Pancreas in Multiple Endocrine Neoplasia Type 1
Lewis, M. A., Thompson, G. B., & Young, W. F. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1539-7 · Cited by 42
Pancreatic neuroendocrine tumors: A comprehensive review
Zhou, C., Zhang, J., Zheng, Y. F., & Zhu, Z. (2012) · International Journal of Cancer · doi:10.1002/ijc.27543 · Cited by 47
Nölting, S., Kuttner, A. J., Lauseker, M., Vogeser, M., Haug, A. R., Herrmann, K. A., Hoffmann, J. N., Spitzweg, C., Göke, B., & Auernhammer, C. J. (2012) · Cancers · doi:10.3390/cancers4010141 · Cited by 41
Jilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26
Dahdaleh, F. S., Calva‐Cerqueira, D., Carr, J. C., Liao, J., Mezhir, J. J., O’Dorisio, T. M., & Howe, J. R. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1997-4 · Cited by 24
Bech, P., Martin, N. M., Ramachandran, R., & Bloom, S. R. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213489670 · Cited by 25
Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors
Shanahan, M. A., Salem, A., Fisher, A. V., Cho, C. S., LEVERSON, G. E., Winslow, E. R., & Weber, S. M. (2015) · Journal of Surgical Research · doi:10.1016/j.jss.2015.10.006 · Cited by 23
Treatment strategies for Zollinger–Ellison syndrome
Wilcox, C. M., & Hirschowitz, B. I. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902887035 · Cited by 26
Buil‐Bruna, N., Dehez, M., Manon, A., Nguyen, T. X. Q., & Trocóniz, I. F. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9884-3 · Cited by 23
Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Angelini, F., Baldelli, R., Berretti, D., Bianchetti, S., Bizzarri, G., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0119-0 · Cited by 23
Smolková, B., Kataki, A., Earl, J., Ruz‐Caracuel, I., Cihova, M., Urbanova, M., Buociková, V., Tamargo, S., Rovīte, V., Niedra, H., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103865 · Cited by 21
Fisher, A. V., Lopez‐Aguiar, A. G., Rendell, V. R., Pokrzywa, C. J., Rocha, F. G., Kanji, Z. S., Poultsides, G. A., Makris, E. A., Dillhoff, M. E., Beal, E. W., et al. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-04080-1 · Cited by 21
Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors
Raoof, M., Jutric, Z., Melstrom, L. G., Lee, B., Li, D., Warner, S. G., Fong, Y., & Singh, G. P. (2018) · Surgery · doi:10.1016/j.surg.2018.10.018 · Cited by 22
Chromogranin As a Biochemical Marker of Neuroendocrine Tumors
Lyubimova, N. V., Churikova, T. K., & Kushlinskii, N. E. (2016) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-016-3254-0 · Cited by 20
Mandair, D., Khan, M. S., Lopes, A., O’Mahony, L. F., Ensell, L., Lowe, H. L., Hartley, J. A., Toumpanakis, C., Caplin, M. E., & Meyer, T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa822 · Cited by 21
Kulke, M. H., Ruszniewski, P. B., Cutsem, E. V., Lombard‐Bohas, C., Valle, J. W., de Herder, W. W., Pavel, M. E., Degtyarev, E., Brase, J., Bubuteishvili‐Pacaud, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz219 · Cited by 20
Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo
Tian, Y., Liang, Z. C., Bai, J., Mei, Y., Li, Z., Lin, A., & Li, X. (2017) · Pancreas · doi:10.1097/mpa.0000000000000895 · Cited by 18
Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
Baekdal, J., Krogh, J., Klose, M., Holmager, P., Langer, S. W., Oturai, P., Kjaer, A., Federspiel, B., Hilsted, L., Rehfeld, J. F., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10110881 · Cited by 17
Cromogranina A y tumores neuroendocrinos
Pérez, J. Á. D., & Freixes, M. C. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.10.003 · Cited by 19
on behalf of the “G-NET-Registry” investigators, Nikou, G. C., Pazaitou‐Panayiotou, K., Dimitroulopoulos, D., Alexandrakis, G., Papakostas, P., Vaslamatzis, M., Kaldrymidis, P., Markussis, V., & Koumarianou, A. A. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0089-7 · Cited by 16
Self-citationPediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature
Gaiani, F., de’Angelis, N., Minelli, R., Kayali, S., Carra, M. C., & de’Angelis, G. L. (2019) · Medicine · doi:10.1097/md.0000000000017154 · Cited by 13
Mirkin, K. A., Hollenbeak, C. S., & Wong, J. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.12.033 · Cited by 13
Rogowski, W., Wachuła, E., Lewczuk, A., Kolasińska, A. D., Iżycka‐Świeszewska, E., Sulżyc‐Bielicka, V., & Ćwikła, J. B. (2017) · Future Oncology · doi:10.2217/fon-2016-0455 · Cited by 13
Do, M. Y., Jang, S. I., Kang, H., Kim, E. J., Lee, K.-J., Park, G. E., Lee, S.-J., Lee, D. K., Woo, S. M., & Cho, J. H. (2021) · Cancers · doi:10.3390/cancers13184713 · Cited by 12
Chromogranin A and neuroendocrine tumors
Pérez, J. Á. D., & Freixes, M. C. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.10.007 · Cited by 14
Tian, B., Yang, M., Zhang, Y., Su, A., Yue, P., Xu, S., & Wang, L. (2015) · Indian Journal of Cancer · doi:10.4103/0019-509x.176746 · Cited by 11
Khan, T. M., Garg, M., Warner, R. R. P., Uhr, J. H., & Divino, C. M. (2015) · Pancreas · doi:10.1097/mpa.0000000000000572 · Cited by 11
Papantoniou, D., Grönberg, M., Landerholm, K., Welin, S., Ziółkowska, B., Nordvall, D., & Janson, E. T. (2020) · Endocrine · doi:10.1007/s12020-020-02534-8 · Cited by 11
Luboldt, W., Hartmann, H., Wiedemann, B., Zöphel, K., & Luboldt, H. (2010) · Molecular Imaging · doi:10.2310/7290.2010.00035 · Cited by 8
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Meng, Q. H., Halfdanarson, T. R., Bornhorst, J. A., Jann, H., Shaheen, S., Shi, R., Schwabe, A., Stade, K., & Halperin, D. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1875 · Cited by 7
A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours
Topping, M., Gray, D., Friend, E., Davies, A. H., & Ramage, J. K. (2017) · Neuroendocrinology · doi:10.1159/000475793 · Cited by 7
Kohno, S. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10085 · Cited by 6
Hayes, A. R., Mak, I. Y. F., Evans, N., Naik, R., Crawford, A., Khoo, B. C. E., Grossman, A. B., Navalkissoor, S., Watkins, J., Luong, T. V., et al. (2020) · Neuroendocrinology · doi:10.1159/000511662 · Cited by 6
Circulating Tumor Markers in Patients with Neuroendocrine Tumors – a Clinical Perspective
Halfdanarson, T. R., Howe, J. R., Haraldsdóttir, S., & O’Dorisio, T. M. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.38 · Cited by 5
Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors
Lyubimova, N. V., Timofeev, Y. S., Churikova, T. K., Евгеньевич, К. А., & Евгеньевич, К. Н. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-2-17(392)-19-22 · Cited by 5
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases
Kim, M. K., Ye, F., Wang, D., Cui, M., Ward, S. C., Warner, R. R. P., Roayaie, S., Shafir, M. K., Schwartz, M., Zhang, D. E. W., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000459 · Cited by 4
Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia
Gori, G., Spinelli, G., Spinelli, C., Tuccori, M., Blandizzi, C., & Tacca, M. D. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.152 · Cited by 4
BIOCHEMICAL MARKERS IN SERUM AND URINE IN THE WORKUP OF PATIENTS WITH NEUROENDOCRINE TUMORS
Lyubimova, N. V., & Кушлинский, Н. Е. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2016-44-4-439-450 · Cited by 3
CLINICAL VALUE OF CHROMOGRANIN A IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS
Lyubimova, N. V., Томс, М. Г., Churikova, T. K., & Kharitid, T. Y. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2015-41-35-39 · Cited by 2
Rorstad, O. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803412-5.00009-4 · Cited by 2
Røseth, A. G., Chapman, R., Ramachandran, R., & Sheehan, C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-08-097037-0.00070-1 · Cited by 2
Clinical Implications of Neuroendocrine Tumors
Nikou, G. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-68873-2_66 · Cited by 2
Self-citationIntroduction to Neuroendocrine Tumors
Nikou, G. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-68873-2_64 · Cited by 2
Self-citationClinical Implications of Neuroendocrine Tumors
Nikou, G. C. (2013) · Springer eBooks · doi:10.1007/978-88-470-5385-4_68 · Cited by 1
Self-citationMultiple endocrine neoplasia type 1: a case report and review of the literature
Šileikis, A., Kildušis, E., Janavičius, R., & Strupas, K. (2014) · Open Medicine · doi:10.2478/s11536-013-0297-8 · Cited by 1
Introduction to Neuroendocrine Tumors
Nikou, G. C. (2013) · Springer eBooks · doi:10.1007/978-88-470-5385-4_66 · Cited by 1
Self-citationInvolvement of Chromogranin A and Its Derived Peptides to Fight Infections
Metz‐Boutigue, M., & Schneider, F. (2017) · UNIPA Springer series · doi:10.1007/978-3-319-58338-9_4 · Cited by 1
Neuroendocrine Neoplasms (NENs)
Fazio, N., Spada, F., Rossi, R. E., Ambrosini, V., Incorvaia, L., Passiglia, F., Cani, M., & Badalamenti, G. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_60 · Cited by 1
Zyromski, N. J., Lewellen, K. A., Maatman, T. K., & McGuire, S. P. (2024) · Pancreas · doi:10.1097/mpa.0000000000002428 · Cited by 1
Zibert, K. C., & Hobbs, C. (2014) · Case Reports in Internal Medicine · doi:10.5430/crim.v2n1p73
Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Zini, M., Nuova, S. M., Papini, E., Angelini, F., Bianchetti, S., Baldelli, R., et al. (2014)
Diagnosis and Staging of Pancreatic Malignancies
Chawla, S., Mekaroonkamol, P., & Willingham, F. F. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814618991_0014 · Cited by 1
Tumores neuro-endócrinos do Pâncreas
Pereira, I. B. S. D. A. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/6g7k-9x75
Metastatic malignant liver tumors
Khan, S., Nagorney, D. M., & Que, F. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00127-2
Hepatic metastasis from neuroendocrine cancers
Smoot, R. L., Khan, S., & Nagorney, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00093-5
Pancreatic Neuroendocrine Tumors
Chagpar, R., Naples, R. F., & SIPERSTEIN, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00084-0
Gantenbein, N., & Haybaeck, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_7
Clinical and Molecular Prognostic Factors in Neuroendocrine Neoplasms
Ramachandran, A., & Lawrence, B. J. (2025) · Endocrinology · doi:10.1007/978-3-030-67823-4_5-1
Clinical and Molecular Prognostic Factors in Neuroendocrine Neoplasms
Ramachandran, A., & Lawrence, B. J. (2025) · Endocrinology · doi:10.1007/978-3-031-83281-9_5
Metadata
- Authors
- Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Hippocration General Hospital (GR)
- Corresponding author
- Nikou, G.C.
- Venue
- Pancreatology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 8
- Issue
- 4-5
- Pages
- 510-519
- ISSN
- 1424-3903 (ISSN-L)
- OpenAlex
- W1993526737
- Cited by
- 84
- References
- 30
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 7 · 2013: 6 · 2012: 8
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Pancreatology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- chromogranin A, serum biomarkers, liver metastasis, octreoscan, somatostatin receptor imaging, tumor progression, treatment response monitoring, multiple endocrine neoplasia type 1, surgical resection, mesenteric metastases, dyspepsia, weight loss, tumor differentiation, prognosis, follow-up
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Biomarkers, Tumor, Chemoembolization, Therapeutic, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Chromogranin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.